Arctic Bioscience – The HeROPA phase IIb clinical trial approved in Norway, Finland, Germany and Poland
Reference is being made to the stock exchange release from January 12[th], 2023, where Arctic Bioscience announced that the Clinical Trial Application (CTA) for a phase IIb clinical trial in mild-to-moderate psoriasis with the investigational medicinal product HRO350 was approved in the United Kingdom (UK). Arctic Bioscience is pleased to announce that the CTA also has been approved in Norway, Finland, Germany and Poland.As announced on January 31[st], 2023, Arctic Bioscience met a key milestone when the first patient was included in the clinical trial “A phase IIb, multicenter, randomized,